FDA expands Xtandi's prostate cancer use

The FDA on 10 September gave Medivation and Astellas the go-ahead to market Xtandi (enzalutamide/MDV3100) as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) not previously treated with chemotherapy – expanding the drug's use.

The FDA on 10 September gave Medivation and Astellas the go-ahead to market Xtandi (enzalutamide/MDV3100) as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) not previously treated with chemotherapy – expanding the drug's use.

The companies initially won approval of Xtandi, an oral, once-daily androgen receptor inhibitor, in August 2012 as a treatment for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category